N4P.L

N4 Pharma Plc
N4 Pharma PLC - SRI Research Update
17th September 2024, 07:04
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 4828E
N4 Pharma PLC
17 September 2024
 

17 September 2024

N4 Pharma plc

("N4 Pharma" or the "Company")

 

SRI Research Update

 

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments, gene therapy and vaccines, is pleased to provide a further update on its work with SRI International ("SRI").

 

Further to the Company's announcement on 20 August 2024, the Company has now successfully demonstrated that the selected cargo, when combined with Nuvec® and SRI's Fox Three Molecular Guidance System ("MGS"), is performing as expected  and has therefore completed the first stage of its collaboration project with SRI.  More information will be released soon.

 

Find more information and an additional video by Nigel Theobald, CEO and submit any questions via the N4 Pharma investor hub: https://investors.n4pharma.com/link/MrDmnP.

 

 

 

Nigel Theobald, Chief Executive Officer of the Company, commented:

 

"We have now shown that not only is Nuvec® capable of modification with a ligand to target specific cells, but also that the combined new Nuvec® nanoparticle retains its ability to knockdown the target gene.

 

"We will add this information to our combined marketing pitch deck and both SRI and N4 Pharma will present this data and its implications to major pharma and biotech players that need a targeting delivery system for their nucleic acid programs."

 

 

For more information please contact:

 

N4 Pharma plc

Nigel Theobald, CEO

Luke Cairns, Executive Director

 

Engage with us directly at N4 Pharma Investor Hub

 

To hear more, visit

 

Via N4 Pharma Investor Hub

 

 

Sign up at investors.n4pharma.com

 

 

SP Angel Corporate Finance LLP

Nominated Adviser and Joint Broker

Matthew Johnson/Caroline Rowe (Corporate Finance)

Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)

Tel: +44(0)20 3470 0470

Turner Pope Investments (TPI) Limited

Joint Broker

Andy Thacker

James Pope

Tel: +44(0)20 3657 0050



 

 

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for oncology, gene therapy and vaccines using its unique silica nanoparticle delivery system called Nuvec® and Liptide, a unique peptide/lipid delivery system via its subsidiary Nanogenics.

 

N4 Pharma's business model is to partner with companies developing products in these fields to use Nuvec® or Liptide® as the delivery vehicle for these products. As these products progress through pre‐clinical and clinical programs, N4 Pharma will seek to receive upfront payments, milestone payments and ultimately royalty payments once products reach the market.

 

For further information on the Company visit www.n4pharma.com or sign up at investors.n4pharma.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDQKOBKOBKKDCD]]>
TwitterFacebookLinkedIn